Amgen (AMGN)
Amgen R&D Expense: 736.00M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
AMGN R&D Expense Rankings
| Overall | 1st percentile | 1734 of 1764 |
| Sector | 2nd percentile | 403 of 413 in Healthcare |
| Industry | 0th percentile | 150 of 150 in Biotechnology |
AMGN R&D Expense Range, Past 5 Years
| Minimum | 633.00M | Mar 2009 |
| Maximum | 891.00M | Dec 2009 |
| Average | 755.30M |
About R&D Expense
R&D expenses are a line item from many companies' income statements.
R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.
Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.
An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More
You may also be interested in these AMGN related companies
AMGN News
$AMGN http://stks.co/3zIU Odds for daily bounce from 50sma and weekly 20sma and for possible swing trade http://stks.co/3zIV
about 2 days ago by xpertstocktrader
about 2 days ago by xpertstocktrader
$AMGN Mentioned more than normal on StockTwits - Currently at 3 x average daily social activity
about 3 days ago by TradeIdeasQuant
about 3 days ago by TradeIdeasQuant
$AMGN 69.15 a tough nut to crack, past resistance, but has that look it wants more
about 3 days ago by harmongreg
about 3 days ago by harmongreg
Analyst Sees Affymax's (AFFY) Omontys as Comparable to Amgen's (AMGN) Epogen; Raises AFFY Target to $21
May 21, 12:17PM Street Insider
May 21, 12:17PM Street Insider
$IBB $XHB $SPY $XLK $AMGN
4 Industry Groups Beating the S&P 500
http://stks.co/3tZG
about 9 days ago by TomAspray
about 9 days ago by TomAspray
$AMGN Mentioned more than normal on StockTwits - Currently at 4 x average daily social activity
about 10 days ago by TradeIdeasQuant
about 10 days ago by TradeIdeasQuant
$AMGN http://stks.co/3sFt UPDATE: Asc Triangle #Pattern breakout target. #Wave 5 UP & 3 DOWN scenarios targets. Long Jun calls
about 10 days ago by RatioCynic
about 10 days ago by RatioCynic
$AMGN http://stks.co/3s4u Nice daily continuation pattern . So far own way chart http://stks.co/3s4v
about 10 days ago by xpertstocktrader
about 10 days ago by xpertstocktrader
Amgen (AMGN) Says AMG 103 Achieves High-Rate of CR in B-Precursor ALL Following Phase 2 Data
May 16, 6:05PM Street Insider
May 16, 6:05PM Street Insider
Amgen (AMGN) Updates on Exploratory Biomarker Analysis for AMG 102 Response Predictor
May 16, 6:04PM Street Insider
May 16, 6:04PM Street Insider
$AMGN http://stks.co/3oda BIG PICTURE! Symm Triangle #Pattern & #Wave targets. 15 Yr rising channel. Bullish $Flows.
about 13 days ago by RatioCynic
about 13 days ago by RatioCynic
Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
May 01, 5:03PM PR Newswire
May 01, 5:03PM PR Newswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AMGN | 69.05 | -0.05 | -0.07% | 54.16B |
| AMG | 103.47 | -0.33 | -0.32% | 5.356B |
| AME | 49.22 | -0.44 | -0.89% | 7.911B |
| AMD | 6.22 | +0.20 | +3.32% | 4.350B |
| AIQ | 1.05 | -0.02 | -1.87% | 55.99M |
| AINV | 7.46 | -0.03 | -0.40% | 1.470B |
| AIN | 18.72 | +0.45 | +2.46% | 585.94M |
| AIMC | 17.11 | -0.24 | -1.38% | 460.94M |
| ALC | 14.57 | -0.13 | -0.88% | 334.67M |
| ALB | 61.43 | +0.94 | +1.55% | 5.464B |
